Abstract 1009P - Integrated biomarker analysis of brigatinib efficacy in Anaplastic Lymphoma Kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
https://oncologypro.esmo.org/meeting-resources/esmo-congress/integrated-biomarker-analysis-of-brigatinib-efficacy-in-anaplastic-lymphoma-kinase-positive-alk-non-small-cell-lung-cancer-nsclc-refractory-to

  Abstract 1156P - Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK+) non‒small cell lung cancer (NSCLC): results from the ALTA-1L trial
https://oncologypro.esmo.org/meeting-resources/esmo-congress/quality-adjusted-survival-with-brigatinib-brg-versus-crizotinib-crz-in-alk-positive-alk-non-small-cell-lung-cancer-nsclc-results-from-the

  Abstract 988P - Phase 1/2 study of mobocertinib in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Updated results from platinum- pretreated patients (PPP)
https://oncologypro.esmo.org/meeting-resources/esmo-congress/phase-i-ii-study-of-mobocertinib-in-egfr-exon-20-insertion-ex20ins-metastatic-nsclc-mnsclc-updated-results-from-platinum-pretreated-patients

  Abstract 1087P - Predictive value of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) in patients (pts) with EGFR exon 20 insertion (ex20ins)‒positive metastatic non‒small cell lung cancer (mNSCLC) receiving mobocertinib therapy
https://oncologypro.esmo.org/meeting-resources/esmo-congress/predictive-value-of-krebs-von-den-lungen-6-kl-6-and-surfactant-protein-d-sp-d-in-patients-pts-with-egfr-exon-20-insertion-ex20ins-positive

  Abstract 1111P - Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global expanded access program (EAP)
https://oncologypro.esmo.org/meeting-resources/esmo-congress/real-world-treatment-duration-in-patients-with-non-small-cell-lung-cancer-nsclc-with-egfr-exon-20-insertion-egfrex20ins-mutations-receiving-mob

  Abstract 1001P - Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
https://oncologypro.esmo.org/meeting-resources/esmo-congress/epidermal-growth-factor-receptor-egfr-testing-and-treatment-patterns-associated-with-diagnosis-of-non-small-cell-lung-cancer-nsclc-with-egfr-ex

For Healthcare Professionals Only
VV-MEDMAT-74116 Sep 2022